The latest national LC guideline from 2014 only mentions epidermal growth factor receptor (EGFR) testing and guided therapy for lung adenocarcinoma as optional, without mention of programmed death ligand 1 testing or specific therapy.14 A Colombian consensus on advanced LC addressed PDL1, EGFR, ALK, and ROS1. 15 Molecular testing for cancer of unknown primary (CUP) is not covered in any national guideline. This evidence concerns the gene ROS1 and laryngotracheoesophageal cleft.